Literature DB >> 34852175

Disease progression and clinical outcomes in telomere biology disorders.

Marena R Niewisch1, Neelam Giri1, Lisa J McReynolds1, Rotana Alsaggaf1, Sonia Bhala1, Blanche P Alter1, Sharon A Savage1.   

Abstract

Dyskeratosis congenita related telomere biology disorders (DC/TBDs) are characterized by very short telomeres caused by germline pathogenic variants in telomere biology genes. Clinical presentations can affect all organs, and inheritance patterns include autosomal dominant (AD), autosomal recessive (AR), X-linked (XLR), or de novo. This study examined the associations between mode of inheritance with phenotypes and long-term clinical outcomes. Two hundred thirty-one individuals with DC/TBDs (144 male, 86.6% known genotype, median age at diagnosis 19.4 years [range 0 to 71.6]), enrolled in the National Cancer Institute's Inherited Bone Marrow Failure Syndrome Study, underwent detailed clinical assessments and longitudinal follow-up (median follow-up 5.2 years [range 0 to 36.7]). Patients were grouped by inheritance pattern, considering AD-nonTINF2, AR/XLR, and TINF2 variants separately. Severe bone marrow failure (BMF), severe liver disease, and gastrointestinal telangiectasias were more prevalent in AR/XLR or TINF2 disease, whereas pulmonary fibrosis developed predominantly in adults with AD disease. After adjusting for age at DC/TBD diagnosis, we observed the highest cancer risk in AR/XLR individuals. At last follow-up, 42% of patients were deceased with a median overall survival (OS) of 52.8 years (95% confidence interval [CI] 45.5-57.6), and the hematopoietic cell or solid organ transplant-free median survival was 45.3 years (95% CI 37.4-52.1). Significantly better OS was present in AD vs AR/XLR/TINF2 disease (P < .01), while patients with AR/XLR and TINF2 disease had similar survival probabilities. This long-term study of the clinical manifestations of DC/TBDs creates a foundation for incorporating the mode of inheritance into evidence-based clinical care guidelines and risk stratification in patients with DC/TBDs. This trial was registered at www.clinicaltrials.gov as #NCT00027274.
© 2022 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34852175      PMCID: PMC8952184          DOI: 10.1182/blood.2021013523

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   25.476


  63 in total

1.  Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study.

Authors:  Blanche P Alter; Neelam Giri; Sharon A Savage; June A Peters; Jennifer T Loud; Lisa Leathwood; Ann G Carr; Mark H Greene; Philip S Rosenberg
Journal:  Br J Haematol       Date:  2010-04-30       Impact factor: 6.998

2.  Cerebroretinal microangiopathy with calcifications and cysts.

Authors:  T Linnankivi; L Valanne; A Paetau; I Alafuzoff; J M Hakumäki; T Kivelä; T Lönnqvist; O Mäkitie; L Pääkkönen; L Vainionpää; R Vanninen; R Herva; H Pihko
Journal:  Neurology       Date:  2006-08-30       Impact factor: 9.910

3.  Myelodysplasia and liver disease extend the spectrum of RTEL1 related telomeropathies.

Authors:  Shirleny R Cardoso; Alicia C M Ellison; Amanda J Walne; David Cassiman; Manoj Raghavan; Bhuvan Kishore; Philip Ancliff; Carmen Rodríguez-Vigil; Bieke Dobbels; Ana Rio-Machin; Ahad F H Al Seraihi; Nikolas Pontikos; Hemanth Tummala; Tom Vulliamy; Inderjeet Dokal
Journal:  Haematologica       Date:  2017-05-11       Impact factor: 9.941

Review 4.  Late Effects Screening Guidelines after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects After Pediatric HCT.

Authors:  Andrew C Dietz; Sharon A Savage; Adrianna Vlachos; Parinda A Mehta; Dorine Bresters; Jakub Tolar; Carmem Bonfim; Jean Hugues Dalle; Josu de la Fuente; Roderick Skinner; Farid Boulad; Christine N Duncan; K Scott Baker; Michael A Pulsipher; Jeffrey M Lipton; John E Wagner; Blanche P Alter
Journal:  Biol Blood Marrow Transplant       Date:  2017-05-19       Impact factor: 5.742

5.  Telomere shortening in familial and sporadic pulmonary fibrosis.

Authors:  Jennifer T Cronkhite; Chao Xing; Ganesh Raghu; Kelly M Chin; Fernando Torres; Randall L Rosenblatt; Christine Kim Garcia
Journal:  Am J Respir Crit Care Med       Date:  2008-07-17       Impact factor: 21.405

Review 6.  Understanding the evolving phenotype of vascular complications in telomere biology disorders.

Authors:  Cecilia Higgs; Yanick J Crow; Denise M Adams; Emmanuel Chang; Don Hayes; Utz Herbig; James N Huang; Ryan Himes; Kunal Jajoo; F Brad Johnson; Susan D Reynolds; Yoshihiro Yonekawa; Mary Armanios; Farid Boulad; Courtney D DiNardo; Carlo Dufour; Frederick D Goldman; Shakila Khan; Christian Kratz; Kasiani C Myers; Ganesh Raghu; Blanche P Alter; Geraldine Aubert; Sonia Bhala; Edward W Cowen; Yigal Dror; Mounif El-Youssef; Bruce Friedman; Neelam Giri; Lisa Helms Guba; Payal P Khincha; Tiffany F Lin; Hilary Longhurst; Lisa J McReynolds; Adam Nelson; Tim Olson; Anne Pariser; Rosario Perona; Ghadir Sasa; Kristen Schratz; Douglas A Simonetto; Danielle Townsley; Michael Walsh; Katherine Stevens; Suneet Agarwal; Alison A Bertuch; Sharon A Savage
Journal:  Angiogenesis       Date:  2018-08-25       Impact factor: 9.596

7.  Telomere length measurement can distinguish pathogenic from non-pathogenic variants in the shelterin component, TIN2.

Authors:  T Vulliamy; R Beswick; M J Kirwan; U Hossain; A J Walne; I Dokal
Journal:  Clin Genet       Date:  2011-01-04       Impact factor: 4.438

8.  Dyskeratosis congenita induced cirrhosis for liver transplantation-perioperative management.

Authors:  Anshuman Singh; V K Pandey; Manish Tandon; C K Pandey
Journal:  Indian J Anaesth       Date:  2015-05

9.  Biallelic mutations in WRAP53 result in dysfunctional telomeres, Cajal bodies and DNA repair, thereby causing Hoyeraal-Hreidarsson syndrome.

Authors:  Ann Nordgren; Marianne Farnebo; Sofie Bergstrand; Stefanie Böhm; Helena Malmgren; Anna Norberg; Mikael Sundin
Journal:  Cell Death Dis       Date:  2020-04-17       Impact factor: 8.469

10.  Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease.

Authors:  Benedetta Donati; Alessandro Pietrelli; Piero Pingitore; Paola Dongiovanni; Andrea Caddeo; Lucy Walker; Guido Baselli; Serena Pelusi; Chiara Rosso; Ester Vanni; Ann Daly; Rosellina Margherita Mancina; Antonio Grieco; Luca Miele; Stefania Grimaudo; Antonio Craxi; Salvatore Petta; Laura De Luca; Silvia Maier; Giorgio Soardo; Elisabetta Bugianesi; Fabio Colli; Renato Romagnoli; Quentin M Anstee; Helen L Reeves; Anna Ludovica Fracanzani; Silvia Fargion; Stefano Romeo; Luca Valenti
Journal:  Cancer Med       Date:  2017-07-04       Impact factor: 4.452

View more
  5 in total

Review 1.  Genetics of human telomere biology disorders.

Authors:  Patrick Revy; Caroline Kannengiesser; Alison A Bertuch
Journal:  Nat Rev Genet       Date:  2022-09-23       Impact factor: 59.581

Review 2.  Clonal Hematopoiesis and Myeloid Neoplasms in the Context of Telomere Biology Disorders.

Authors:  Alejandro Ferrer; Abhishek A Mangaonkar; Mrinal M Patnaik
Journal:  Curr Hematol Malig Rep       Date:  2022-05-07       Impact factor: 4.213

3.  A Rare Heterozygous TINF2 Deletional Frameshift Mutation in a Chinese Pedigree With a Spectrum of TBDs Phenotypes.

Authors:  Hai-Long Ren; Ying-Chun Zheng; Guo-Qian He; Ju Gao; Xia Guo
Journal:  Front Genet       Date:  2022-07-07       Impact factor: 4.772

Review 4.  Fanconi anemia and dyskeratosis congenita/telomere biology disorders: Two inherited bone marrow failure syndromes with genomic instability.

Authors:  Moisés Ó Fiesco-Roa; Benilde García-de Teresa; Paula Leal-Anaya; Renée van 't Hek; Talia Wegman-Ostrosky; Sara Frías; Alfredo Rodríguez
Journal:  Front Oncol       Date:  2022-08-25       Impact factor: 5.738

5.  Domain specific mutations in dyskerin disrupt 3' end processing of scaRNA13.

Authors:  Neha Nagpal; Albert K Tai; Jayakrishnan Nandakumar; Suneet Agarwal
Journal:  Nucleic Acids Res       Date:  2022-08-26       Impact factor: 19.160

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.